After the recent news of Eohilia's approval, Sanofi was looking to reinforce Dupixent's standing in the market by showing promising data on the effect of Dupixent in patients with EoE at the 2024 American Academy of Allergy, Asthma & Immunology annual meeting held on 23-26 February 2024 demonstrating its potential in transforming the treatment landscape for EoE patients, with a focus on the pediatric group, according to a 9 February press release.